Evidence map›Paper›PMID 40760164›Full record

ArticleNPJ digital medicine2025

Multimodal deep learning model for prognostic prediction in cervical cancer receiving definitive radiotherapy: a multi-center study.

Weiping Wang, Guang Yang, Yulin Liu, Lichun Wei, Xiaoying Xu, Chulong Zhang, Zhaohong Pan, Yongguang Liang, Bo Yang, Jie Qiu and 4 more

Erratum issuedAbstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Weiping Wang *Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Guang Yang *Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Yulin Liu *Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Lichun WeiDepartment of Radiation Oncology, Xijing Hospital, Air Force Military Medical University, Xi'an, China.
Xiaoying XuDepartment of Radiation Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Chulong ZhangShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Zhaohong PanShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Yongguang LiangDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Bo YangDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jie QiuDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Fuquan ZhangDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiaorong HouDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. hxr_pumch@163.com.
Ke HuDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. huke8000@126.com.
Xiaokun LiangShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China. xk.liang@siat.ac.cn.

Funding

National High-Level Hospital Clinical Research Funding 2022-PUMCH-B-116National High-Level Hospital Clinical Research Funding 2022-PUMCH-B-127National Key Research and Development Program of China 2022YFC2402305National Key Research and Development Program of China 2023YFC2411502National Key Research and Development Program of China 2023YFC2411504Peking Union Medical College Hospital Talent Cultivation Program (Category C) No.UBJ04712
6 · The paper itself

Abstract

For patients with locally advanced cervical cancer (LACC), precise survival prediction models could guide personalized treatment. We developed and validated CerviPro, a deep learning-based multimodal prognostic model, to predict disease-free survival (DFS) in 1018 patients with LACC receiving definitive radiotherapy. The model integrates pre- and post-treatment CT imaging, handcrafted radiomic features, and clinical variables. CerviPro demonstrated robust predictive performance in the internal validation cohort (C-index 0.81), and external validation cohorts (C-index 0.70&0.66), significantly stratifying patients into distinct high- and low-risk DFS groups. Multimodal feature fusion consistently outperformed models based on single feature categories (clinical data, imaging, or radiomics alone), highlighting the synergistic value of integrating diverse data sources. By integrating multimodal data to predict DFS and recurrence risk, CerviPro provides a clinically valuable prognostic tool for LACC, offering the potential to guide personalized treatment strategies.

Identifiers

PMID40760164
PMCPMC12322216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.